A5101424513- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- IL-33, ST2, and ILC Pathways
- Eosinophilic Esophagitis
- Sinusitis and nasal conditions
- Respiratory and Cough-Related Research
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- Dermatology and Skin Diseases
- Eosinophilic Disorders and Syndromes
- Pediatric health and respiratory diseases
- Prostate Cancer Treatment and Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Nasal Surgery and Airway Studies
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Peroxisome Proliferator-Activated Receptors
- Head and Neck Surgical Oncology
- Olfactory and Sensory Function Studies
- Autoimmune Bullous Skin Diseases
- T-cell and B-cell Immunology
- Colorectal Cancer Treatments and Studies
- Photoreceptor and optogenetics research
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
Genesis HealthCare
2024
Research Triangle Park Foundation
2019-2024
University of Illinois Chicago
2024
Global Medical Imaging
2023
Synta Pharmaceuticals (United States)
2023
Icahn School of Medicine at Mount Sinai
2022
Oregon Health & Science University
2022
John Hunter Hospital
2021
GlaxoSmithKline (United States)
2010-2021
Australia New Zealand Gynaecological Oncology Group
2021
BackgroundAlterations involving the RET kinase are implicated in pathogenesis of lung, thyroid and other cancers. However, clinical activity multikinase inhibitors (MKIs) with anti-RET RET-altered patients appears limited, calling into question therapeutic potential targeting RET. LOXO-292 is a selective inhibitor designed to inhibit diverse fusions, activating mutations acquired resistance mutations.Patients methodsPotent activity, high selectivity, central nervous system coverage were...
Abstract Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function 1–3 . The interaction of menin with lysine methyltransferase 2A (KMT2A), an regulator, is a dependence acute leukaemia caused by either rearrangement KMT2A or mutation the nucleophosmin 1 gene ( NPM1 ) 4–6 rearrangements occur up to 10% leukaemias and have adverse prognosis, whereas mutations 30%, forming most common genetic alteration myeloid 7,8 Here, we...
BackgroundIn the phase III SYNAPSE study, mepolizumab reduced nasal polyp (NP) size and obstruction in chronic rhinosinusitis with NP.ObjectiveWe sought to assess efficacy of patients from grouped by comorbid asthma, aspirin-exacerbated respiratory disease (AERD), baseline blood eosinophil count (BEC).MethodsSYNAPSE, a randomized, double-blind, 52-week study (NCT03085797), included severe bilateral NP eligible for surgery despite intranasal corticosteroid treatment. Patients received...
Rationale: Group 2 innate lymphoid cells (ILC2), a major source of type cytokines, initiate eosinophilic inflammatory responses in murine models asthma.Objectives: To investigate the role ILC2 allergen-induced airway subjects with atopy and asthma.Methods: Using diluent-controlled allergen challenge crossover study, where all (n = 10) developed early late responses, eosinophilia, increased methacholine responsiveness, bone marrow, blood, sputum samples were collected before after inhalation...
NTRK1, NTRK2 and NTRK3 gene fusions (NTRK fusions) occur in a range of adult cancers. Larotrectinib is potent highly selective ATP-competitive inhibitor TRK kinases has demonstrated activity patients with tumours harbouring NTRK fusions.
In severe asthmatics with persistent airway eosinophilia, blockade of interleukin-5 has significant steroid-sparing effects and attenuates blood sputum eosinophilia. The contribution local maturational processes progenitors within the airways relative to recruitment mature cells from peripheral circulation development eosinophilia is not known. We hypothesize that eosinophilopoiesis may be predominant process drives corticosteroid requirement in asthmatics.In a cross-sectional study, number...
Background The long-term efficacy and safety of mepolizumab for treatment severe eosinophilic asthma are well established. Here, we examine the clinical impact stopping after use. Methods COMET ( NCT02555371 ) was a randomised, double-blind, placebo-controlled, parallel-group, multicentre study. Patients who had completed COLUMBA NCT01691859 or COSMEX NCT02135692 received continuous ≥3 years were randomised 1:1 to stop (switch placebo) continue subcutaneous 100 mg every 4 weeks 52 weeks....
<b><i>Background:</i></b> Allergic asthma is an inflammatory airway disease in which Th2 cytokines play important role. Epithelial-derived interleukin (IL)-25 has been suggested to be the maintenance of Th2-type responses. The effects IL-25 are mediated by receptor, composed two subunits, IL-17RA and IL-17RB. Eosinophils effector cells allergic asthma. role eosinophil function unknown. This study examined expression its receptor on eosinophils asthmatics compared...
Background: The alarmin cytokines IL-25 and IL-33 are key promoters of type 2 inflammation.Basophils respond to cytokines, however the relationship these with basophil activation recruitment in human studies allergic asthma has not been well characterized.This study investigated effect on basophils a model asthma.Methods: 10 mild asthmatics underwent allergen diluent inhalation challenges.Bone marrow aspirates were collected at pre-challenge 24 h (h) post challenge.Peripheral blood sputum...
Abstract Background In the 52‐week Phase III SYNAPSE study, mepolizumab given every 4 weeks (100 mg subcutaneously) reduced nasal polyp (NP) size, improved symptoms and quality of life (QoL), corticosteroid use number sinus surgeries in patients with severe chronic rhinosinusitis polyps (CRSwNP), versus placebo. Because durability mepolizumab's efficacy after discontinuation is poorly understood CRSwNP, was analyzed over a 24‐week follow‐up. Methods Changes from baseline to end treatment...
Whilst prostate cancer is the fourth most common globally, effective therapies for patients with advanced disease are lacking. In recent years, interest in using theranostic agents to treat castrate-resistant (CRPC) and metastatic has emerged. Lu-TLX591 monoclonal antibody a potential agent of significance; however, date, reports on its toxicity efficacy have been limited small clinical trials heavily pretreated patients. This retrospective study describes real-world profile Lu-TLX591....
Glucagon-like peptide-1 (GLP-1) and its receptor are part of the incretin family hormones that regulate glucose metabolism. GLP-1 also has immune modulatory roles.To measure expression (GLP-1R) on eosinophils neutrophils in normal asthmatic subjects evaluate effects a analog eosinophil function.Peripheral blood samples were taken from 10 allergic subjects. GLP-1R was measured neutrophils. Subsequently, underwent allergen diluent inhalation challenges, measured. Purified eosinophils,...
The SYNAPSE study (NCT03085797) demonstrated that mepolizumab decreased nasal polyp (NP) size and obstruction in patients with chronic rhinosinusitis NP (CRSwNP).SYNAPSE, a randomized, double-blind study, included recurrent, refractory, severe CRSwNP, eligible for repeated surgery despite receiving standard of care (SoC). Patients received 4-weekly 100 mg or placebo subcutaneously plus SoC 52 weeks. This post hoc analysis further characterized treatment responses association patient...